Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics

Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Acuitas' LNP technology will support Bayer's in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news